Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases
Open Access
- 28 September 2015
- journal article
- research article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 29 (1) , 92-100
Abstract
Summary: Here, we retrospectively review imaging of 68 consecutive unselected patients with BRAF V600‐mutant metastatic melanoma for organ‐specific response and progression on vemurafenib. Complete or partial responses were less often seen in the central nervous system (CNS) (36%) and bone (16%) compared to lung (89%), subcutaneous (83%), spleen (71%), liver (85%) and lymph nodes/soft tissue (83%), P < 0.001. CNS was also the most common site of progression.Based on this, we tested in vitro the efficacy of the BRAF inhibitors PLX4720 and dabrafenib in the presence of cerebrospinal fluid (CSF). Exogenous CSF dramatically reduced cell death in response to both BRAF inhibitors. Effective cell killing was restored by co‐administration of a PI‐3 kinase inhibitor.We conclude that the efficacy of vemurafenib is variable in different organs with CNS being particularly prone to resistance. Extrinsic factors, such as ERK‐ and PI3K‐activating factors in CSF, may mediate BRAF inhibitor resistance in the CNS.Keywords
Funding Information
- Institute of Cancer Research
- Novartis
- Pfizer
This publication has 27 references indexed in Scilit:
- Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK SignalingCancer Cell, 2015
- Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic TargetClinical Cancer Research, 2014
- The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibitionCancer, 2014
- Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot studyEuropean Journal of Cancer, 2014
- Emerging insights into resistance to BRAF inhibitors in melanomaBiochemical Pharmacology, 2014
- Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanomaMolecular Oncology, 2014
- Patterns of response and progression in patients with BRAF‐mutant melanoma metastatic to the brain who were treated with dabrafenibCancer, 2013
- In vivo fluorescence resonance energy transfer imaging reveals differential activation of Rho-family GTPases in glioblastoma cell invasionJournal of Cell Science, 2012
- Oncogenic Braf Induces Melanocyte Senescence and Melanoma in MiceCancer Cell, 2009
- Comparison of the growth hormone, IGF‐1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controlsEuropean Journal of Neurology, 2006